Recent news coverage primarily relates to commodity price movements and general market trends, with no direct recent business developments reported for Bio-Path Holdings, Inc.

• Crude oil prices plummeted on speculation that the Strait of Hormuz could soon reopen, impacting energy markets [N1].
• Sugar prices erased early gains following the plunge in crude oil prices [N2].
• Cocoa prices consolidated recent losses amid market fluctuations [N3].
• Stocks climbed on lower bond yields and strength in chipmaker sectors [N4].
• Stocks rallied as crude oil and bond yields declined [N5].
• Occidental Petroleum moved up in market cap rankings, passing Take-Two Interactive Software [N6].
• Natural gas prices retreated on expectations for increased US storage levels [N7].
• Coffee prices fell due to improved Brazil coffee crop prospects [N8].

The company’s efforts to restructure its finances, engage strategic advisors, and restart clinical trials could enable it to unlock value from its drug development pipeline. The establishment of a Scientific Advisory Board and pursuit of partnerships or mergers may provide pathways to advance its drug candidates and improve operational stability.

Significant risks include the operational pause leading to loss of key personnel and institutional knowledge, ongoing liquidity constraints with a current ratio of 0.07, and substantial doubt about the company’s ability to continue as a going concern. Failure to secure financing or successfully restructure could result in further operational disruptions or delisting from public markets.

Bio-Path's moat is primarily based on its proprietary drug candidates and clinical research pipeline targeting specific diseases such as AML and solid tumors. However, the operational pause and funding challenges have limited its ability to advance these assets. The company’s scientific advisory board and potential strategic partnerships may provide some competitive advantage, but the lack of current operational activity and financial constraints weaken its moat.

• Operational Pause Risks: The operational pause and furlough of most employees may result in loss of institutional knowledge, employee attrition beyond intended levels, decreased morale, and inability to pursue new opportunities effectively.
• Liquidity and Going Concern: As of March 31, 2026, the company has very limited liquidity with a current ratio of 0.07 and zero cash on hand, raising substantial doubt about its ability to continue as a going concern without additional capital.
• Funding and Turnaround Execution: The company’s turnaround plan depends on successfully raising capital, engaging new auditors, hiring investment bankers, and executing strategic mergers or partnerships, with no assurance of success.
• Clinical Trial Restart Uncertainty: Negotiations to restart Phase 1 and Phase 2 drug trials face uncertainties including preserving drug supplies and obtaining shelf-life extensions, which may impact development timelines and costs.

• Bio-Path Holdings, Inc. is a biotechnology company referenced as Bio-Path.
• The company implemented an operational pause on June 24, 2025, to conserve capital while seeking fundraising transactions, resulting in furlough of most employees to reduce expenses.
• The operational pause may cause unintended consequences such as loss of institutional knowledge, employee attrition beyond intended levels, decreased morale, and difficulty pursuing new opportunities due to insufficient personnel.
• Bio-Path is seeking financing to support a planned turnaround, including updating the finance team, engaging new auditors, hiring investment bankers to review its biotech portfolio for sale or partnerships, and pursuing strategic mergers and acquisitions.
• There is substantial doubt about the company's ability to continue as a going concern and remain listed on public trading platforms if it cannot raise capital.
• The company domesticated to Wyoming in early 2026 and created a new class of Series S Preferred stock convertible into common shares with voting rights.
• Bio-Path has a Scientific Advisory Board with members appointed in early 2026, including professionals with expertise in clinical research and drug development.
• The company is in various stages of negotiation with creditors and payables to restructure relationships and restart Phase 1 and Phase 2 drug trials targeting AML, solid tumors, obesity, and other conditions.
• Bio-Path intends to preserve drug supplies stored at key vendors and petition for shelf-life extensions, though outcomes are uncertain.
• Financial snapshot as of March 31, 2026, shows current assets of $677,000 and current liabilities of $9,151,000, resulting in a current ratio of 0.07 and cash ratio of 0, indicating very limited liquidity.
• Net income for the quarter ending March 31, 2026, was a loss of $270,000.
• The company reported zero revenue as of fiscal year 2018 and has negative earnings per share, with diluted EPS of -$0.03 as of Q1 2026.
• Bio-Path's common stock is registered on the OTC Pink market under the ticker BPTH.
• The company has engaged advisory firms and created a Strategic Advisory Board to guide its turnaround efforts.
• Recent news unrelated to Bio-Path includes commodity price movements and stock market trends but no direct business developments for Bio-Path.